Bin Wang

Bin Wang has a diverse work experience in various scientific and research roles. They currently work at CLINUVEL PHARMACEUTICALS LTD as a Scientific Affairs professional. Prior to that, they worked at Vyant Bio as a Scientist, where they were involved in developing novel therapies for diseases like Parkinson's and tumor. They also worked at SAHMRI as a Research Officer, focusing on research activities. Bin Wang has experience as a Business Development Manager at Xi'an Zhida Technology Co. Ltd., where they successfully acquired and maintained new product pipelines for a leading nuclear medical device supplier in China. They also have experience as a Researcher at Nanyang Technological University, where they had extensive knowledge in the Hedgehog signaling pathway and basal cell carcinoma. Bin Wang completed their Ph.D. at UNSW Australia, focusing on their research in a specific field.

Bin Wang completed a Bachelor of Science (BS) in Biotechnology from Tongji University in the years 2003 to 2008. Following this, they pursued a Master of Science (MS) in Molecular and Cell Biology and Pharmacology at the University of Wollongong from 2008 to 2011. Lastly, Bin Wang obtained a Doctor of Philosophy (Ph.D.) in Cell Biology and Anatomy from UNSW between 2011 and 2014.